Founded in 2024, Aignosis operates in the AI sector offering AI-based solutions for the early screening of Autism. The company's focus is on improving the accuracy and accessibility of Autism diagnosi...
Funding stage:
Seed
Last funding:
30/09/2026
Total funding:
$416.00K+
Revenue:
Investors
Employee count:
20
Last 90d
20
Last 90d
Web traffic:
3.29K
3.29K
Last 30d
Last 30d
Aignosis: Cap Table Highlights
A snapshot of cap table and shareholder metrics
Total Shareholders4
Latest Filing Date02 Dec 2024- Funding Events2
Event-Based View
Event-Based detailed View by Filings
FAQs on Cap Table of Aignosis
As of 03 December 2024, Aignosis's equity is held by 4 shareholders, with the top three being Divyansh Mangal, Raksheet Jain, and Rajneesh Bhandari.
Divyansh Mangal holds the largest stake in Aignosis at 47.9% as of 03 December 2024.
As of 03 December 2024, founders collectively hold 95.8% equity in Aignosis.
As of 03 December 2024, investors collectively hold 4.2% equity in Aignosis.
Disclaimer
Inc42 Datalabs consolidates intelligence from public records, statutory filings, proprietary research, and vetted third‑party datasets. All information is provided as is—please run your own checks before acting on it. Inc42 Datalabs bears no responsibility for decisions or outcomes based on this data.
Quick Links